There seems to be two well-established camps in the perfusion community who devoutly hold to their particular brand of pump-head technology. This dichotomy, much the same as the American electorate with democrats and republicans, support themselves with rallying cries to battle lest they are forced to acquiesce to economic pressure or the science of technology assessment to change from roller to centrifugal (or the other way around).
This has been an interesting battle over the years, mostly because the question lends itself perfectly to a well-designed, randomized, clinical trial. The intervention is simple and, honestly, even though it hasn't been done, it would be perfect for blinding of observers (other than the perfusionist) such that the outcomes could truly not be disputed.
Non-blinded, randomized trials have been completed comparing these technologies. The most important was reported by Klein et al., involving a total of 1000 patients undergoing "routine" cardiac surgery. 1 Although most outcomes came out as a wash, centrifugal pumps were associated with a decrease in chest tube drainage and decreased transfusion requirements. Unlike most studies evaluating transfusion as a secondary outcome, there were guidelines for transfusion of red cells in this trial and, thus, this finding is comforting to the academic surgeon.
Most importantly, the incidence of neurologic events was significantly decreased in the centrifugal pump group (2.4% vs 5.2%, p<0.05) and this clinical outcome has a strong bearing to all of us.
The remainder of the prospective, randomized studies have been quite small in terms of numbers and, as a consequence, few, if any, have demonstrated any benefit of one arm over the other. A meta-analysis of the randomized trials, including that of Klein, failed to show any clinical benefit, although there was not enough data to assess the neurologic outcome. 2 Finally, there has been one very large retrospective trial of over 4000 patients reported in 2000 by Parolari et al. which suggested that there was a strong association between the use of roller technology to the incidence of permanent neurologic deficit as compared to centrifugal technology (2.6% vs 1.5%, p<0.05). 3 It may be that testing this technology needs to be focused in trials where the risk-to-benefit ratio has a higher yield in terms of the incidence of complications one is trying to prevent. Centrifugal pumps probably have a benefit, but they probably only surface when one is dealing with long pump runs with difficult patients. In the current issue of the journal, Mlejnsky et al. have presented a small, prospective, randomized trial where they have done just that. The authors have targeted a disease in very ill patients with pulmonary hypertension. 4 The nature of the surgery (mandatory deep hypothermic circulatory arrest) demands long pump times and, thus, the model should have been sensitive enough to pick up a benefit should there have been one. In fact, a benefit was demonstrated, with robust rises in surrogate markers of inflammation (IL-6, procalcitonin) in the roller pump group, but not in the centrifugal pump group. Therefore, the flag has been raised and the challenge has been advertised to us. We have the capacity to collaborate now; we have homogeneous groups of patients undergoing deep hypothermic circulatory arrest, such as with pulmonary thromboendarterectomy and aortic arch surgery and, thus, an opportunity avails itself to us. Here's seeing to a fruitful academic year.
